Reversibility of impaired cerebrovascular reactivity in patients with hypertension: comparison of losartan and atenolol
| ISRCTN | ISRCTN77942127 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN77942127 |
| Protocol serial number | N/A |
| Sponsor | University of Glasgow (UK) |
| Funder | University of Glasgow |
- Submission date
- 08/09/2005
- Registration date
- 27/10/2005
- Last edited
- 11/10/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Matthew Walters
Scientific
Scientific
Department of Medicine & Therapeutics
Western Infirmary
44 Church Street
Glasgow
G11 6NT
United Kingdom
| Phone | +44 (0)141 211 2821 |
|---|---|
| gcl203@clinmed.gla.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Reversibility of impaired cerebrovascular reactivity in patients with hypertension: comparison of losartan and atenolol |
| Study objectives | To investigate the effect of both losartan and atenolol upon impaired cerebrovascular reactivity in hypertension. |
| Ethics approval(s) | West Ethics Committee of NHS Greater Glasgow and Clyde, 18/12/2003, ref: 03/118 (1) |
| Health condition(s) or problem(s) studied | Hypertension |
| Intervention | Patients will undergo baseline assessment of cerebrovascular reactivity. Mean flow velocity (MFV) in the middle cerebral artery (MCA) will be measured using transcranial Doppler. Each subject will then receive an intravenous infusion of acetazolamide after which MFV will be measured. MFV in the internal carotid artery and peripheral arterial stiffness using Sphygmocor will also be assessed pre- and post-infusion. Patients then receive a supply of either losartan and atenolol tablets for 4 weeks after which they will undergo cardiovascular reactivity (CVR) assessment as before. A 1-week washout period of no medication will follow, then the protocol repeated with the alternated tablet. |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Losartan, atenolol |
| Primary outcome measure(s) |
Changes in cerebrovascular reactivity. |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 01/02/2006 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Male |
| Target sample size at registration | 13 |
| Key inclusion criteria | 1. Male: 50-80 years 2. Electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) 3. Blood pressure (BP) 150-200/90-115 |
| Key exclusion criteria | 1. >70% internal carotid artery (ICA) stenosis 2. Middle cerebral artery (MCA) stenosis 3. Contra-indication to losartan, atenolol or acetazolamide 4. Serum creatinine >130 µmol/l 5. Prior treatment with angiotensin converting enzyme (ACE)-1/angiotensin II receptor blocker (ARB)/beta blocker unless able to stop 4 weeks prior to recruitment |
| Date of first enrolment | 01/08/2004 |
| Date of final enrolment | 01/02/2006 |
Locations
Countries of recruitment
- United Kingdom
- Scotland
Study participating centre
Western Infirmary
Glasgow
G11 6NT
United Kingdom
G11 6NT
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
11/10/2016: No publications found, verifying study status with principal investigator.
